Treats Moderate. ANDA 203038, held by Glenmark Pharms Ltd. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 203038 (Norethindrone Acetate And Ethinyl Estradiol), held by Glenmark Pharms Ltd, was first approved by FDA on Apr 2, 2015, with 3 approved supplements and 0 published complete response letters.
Norethindrone acetate and ethinyl estradiol tablets are a combination of an estrogen and progestin indicated in a woman with a uterus for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 2, 2015 | Original application | Approved | None posted |
| Norethindrone Acetate And Ethinyl Estradiol0.0025MG;0.5MG · tablet;oral | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Norethindrone Acetate And Ethinyl Estradiol0.005MG;1MG · tablet;oral | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Feb 16, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 26, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 13, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 2, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters